The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
Eur J Haematol
; 85(6): 484-91, 2010 Dec.
Article
en En
| MEDLINE
| ID: mdl-20846301
ABSTRACT
OBJECTIVES:
To estimate the cost-effectiveness of bortezomib (BTZ) compared with dexamethasone (DEX) and lenalidomide plus dexamethasone (LEN/DEX) for the treatment of relapsed/refractory multiple myeloma in Sweden.METHODS:
We used partitioned survival analysis to assess survival data decomposed into three states (i) alive before disease progression; (ii) alive after progression; and (iii) dead. The effects of treatment on time to progression and overall survival (OS) were obtained from published reports of the APEX, MM-009, and MM-010 randomized clinical trials. Costs included drug and administration costs, adverse events, treatment of relapses, and end-of-life costs. Utility estimates were derived from the literature.RESULTS:
BTZ mean OS was 57.4 months compared with 44.6 and 54.1 months for DEX and LEN/DEX, respectively. Mean lifetime direct medical costs per patient were approximately 2010 SEK 1,904,462, 1,278,854, and 2,450,588 for BTZ, DEX, and LEN/DEX, respectively. Mean incremental cost per quality-adjusted life-year of BTZ compared to DEX was 2010 SEK 902,874 (95,073) (95% CI 514,791, 962,416) and was dominant with respect to LEN/DEX.CONCLUSION:
BTZ and LEN/DEX are projected to prolong survival relative to DEX. From a Swedish perspective, BTZ is cost-effective compared to DEX and LEN/DEX.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Pirazinas
/
Ácidos Borónicos
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Mieloma Múltiple
Tipo de estudio:
Clinical_trials
/
Health_economic_evaluation
/
Systematic_reviews
Límite:
Female
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
Europa
Idioma:
En
Revista:
Eur J Haematol
Asunto de la revista:
HEMATOLOGIA
Año:
2010
Tipo del documento:
Article
País de afiliación:
Estados Unidos